Myocardial Ischemia – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, H1 2012', provides an overview of the Myocardial Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Ischemia. 'Myocardial Ischemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myocardial Ischemia.
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myocardial Ischemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Myocardial Ischemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Ischemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Myocardial Ischemia 8
Myocardial Ischemia Therapeutics under Development by Companies 10
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Myocardial Ischemia Therapeutics – Products under Development by Companies 17
Myocardial Ischemia Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Myocardial Ischemia Therapeutics Development 19
Cardium Therapeutics, Inc. 19
Cook Medical Incorporated 20
Advanced Cell Technology, Inc. 21
Cytori Therapeutics, Inc. 22
CardioVascular BioTherapeutics, Inc. 23
Unigene Laboratories, Inc. 24
Viromed Co., Ltd. 25
Baxter Healthcare Corporation 26
Eribis Pharmaceuticals AB 27
Biopeutics co., Ltd. 28
Myocardial Ischemia – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Generx - Drug Profile 35
Annexin Analogs - Drug Profile 36
VM202 - Drug Profile 37
Papeilin - Drug Profile 39
Eprex - Drug Profile 40
FGF-1141 - Drug Profile 41
Evasin-3 - Drug Profile 42
Adenosine - Drug Profile 43
Ranexa - Drug Profile 44
EP 94 - Drug Profile 45
Adipose Tissue-Derived Stem And Regenerative Cells - Drug Profile 46
Autologous Muscle Derived Cells Transplantation - Drug Profile 47
Hemangioblast Cell Program - Drug Profile 48
Adult Autologous CD34+ Stem Cells - Drug Profile 49
MANF - Drug Profile 51
Autologous Bone-Marrow Mononuclear Cells - Drug Profile 52
Myocardial Ischemia Therapeutics – Drug Profile Updates 53
Myocardial Ischemia Therapeutics - Dormant Products 56
Myocardial Ischemia – Product Development Milestones 58
Featured News & Press Releases 58
Appendix 62
Methodology 62
Expert Panel Validation 63
Contact Us 63
Disclaimer 63
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Myocardial Ischemia, H1 2012 9
Products under Development for Myocardial Ischemia – Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 17
Products under Development by Companies, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
Cardium Therapeutics, Inc., H1 2012 20
Cook Medical Incorporated, H1 2012 21
Advanced Cell Technology, Inc., H1 2012 22
Cytori Therapeutics, Inc., H1 2012 23
CardioVascular BioTherapeutics, Inc., H1 2012 24
Unigene Laboratories, Inc., H1 2012 25
Viromed Co., Ltd., H1 2012 26
Baxter Healthcare Corporation, H1 2012 27
Eribis Pharmaceuticals AB, H1 2012 28
Biopeutics co., Ltd., H1 2012 29
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Molecule Type, H1 2012 35
Myocardial Ischemia Therapeutics – Drug Profile Updates 54
Myocardial Ischemia Therapeutics – Dormant Products 57
Myocardial Ischemia Therapeutics – Dormant Products (Contd..1) 58
List of Figures
Number of Products under Development for Myocardial Ischemia, H1 2012 9
Products under Development for Myocardial Ischemia – Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Pre-Clinical Stage Products, H1 2012 17
Assessment by Monotherapy Products, H1 2012 30
Assessment by Combination Products, H1 2012 31
Assessment by Route of Administration, H1 2012 32
Assessment by Stage and Route of Administration, H1 2012 33
Assessment by Molecule Type, H1 2012 34
Assessment by Stage and Molecule Type, H1 2012 35
[Tabellenverzeichnis ausblenden]